Evaluation of Dryness in a Silicone Hydrogel Daily Disposable Contact Lens

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

95 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-17

Study Completion Date

2021-08-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-site, randomized, bilateral, dispensing, parallel design study with two arms to evaluate contact lens related dry eye symptoms and subjective comfort.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Daily Disposable Silicone Hydrogel Multifocal Toric Contact Lenses

NCT04974697

Visual Acuity

COMPLETED NA

Short-Term Clinical Comparison of Two Silicone Hydrogel Daily Disposable Contact Lenses

NCT03139578

Visual Acuity

COMPLETED NA

Comparison of a Silicone Hydrogel Daily Disposable Multifocal Contact Lens to a Marketed Product

NCT05258149

Visual Acuity

COMPLETED NA

Clinical Evaluation of Two Silicone Hydrogel Daily Disposable Contact Lenses

NCT02595502

Vision Disorders

COMPLETED NA

Evaluation of ACUVUE OASYS® 1-Day for Astigmatism Lenses Produced on a New Manufacturing Line

NCT04794270

Visual Acuity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Visual Acuity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ARM 1

Eligible subjects will be randomized to the TEST lens to wear in both eyes for approximately 2 weeks.

Group Type EXPERIMENTAL

ACUVUE Oasys 1-Day

Intervention Type DEVICE

TEST

ARM 2

Eligible subjects will be randomized to the CONTROL lens to wear in both eyes for approximately 2 weeks. Then the subject will receive the TEST lens to wear in both eyes for approximately 2 weeks.

Group Type EXPERIMENTAL

ACUVUE Oasys 1-Day

Intervention Type DEVICE

TEST

Habitual Lens

Intervention Type DEVICE

Subjects' own Habitual Lenses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ACUVUE Oasys 1-Day

TEST

Intervention Type DEVICE

Habitual Lens

Subjects' own Habitual Lenses

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CONTROL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Potential subjects must satisfy all of the following criteria to be enrolled in the study:

1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
3. Between 18 and 59 (inclusive) years of age at the time of screening.
4. Be a daily disposable current soft contact lens wearer in both eyes with a minimum of 6 days/week wear time over the last 1 month by self-report.
5. Have a CLDEQ-8 score of 15 or greater with the habitual lens.
6. Subjects must possess a pair of spectacles for distance correction.
7. Subject's habitual lens must be the following lens types: Alcon DAILIES® Aqua Comfort Plus® , Alcon DAILIES TOTAL1®, CooperVision® clariti® 1 day, CooperVision® MyDay®, or Johnson \& Johnson 1-Day ACUVUE® Moist.
8. The subject's vertex corrected spherical distance refraction must be in the range of -1.00 D to -6.00 D (inclusive) in each eye.
9. The magnitude of subject's vertex corrected refractive cylinder must be less than 1.00 diopter in each eye.

11\. Have spherical best corrected visual acuity of 20/25 or better in each eye.

Exclusion Criteria

\- Potential subjects who meet any of the following criteria will be excluded from participating in the study:

1. Subject's habitual lens is ACUVUE OASYS®1-Day.
2. Currently pregnant or lactating, by self-report.
3. Any ocular or systemic allergies, disease or use of medication which may interfere with contact lens wear (at the discretion of the investigator).
4. Any active ocular abnormalities/conditions that may interfere with contact lens wear (at the discretion of the investigator).
5. Any infectious diseases (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV), by self-report.
6. Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
7. Habitual contact lens wear modality as extended wear (≥1 night per month of extended wear).
8. Habitual contact lens is rigid gas permeable, toric, monovision or multi-focal.
9. . Any previous, or planned (during the course of the study) ocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.).
10. Participation in any contact lens or lens care product clinical trial within 2 weeks prior to study enrollment.
11. Employee or employee's immediate family member of clinical site (e.g., Investigator, Coordinator, Technician).
12. Current habitual use of Restasis, Xiidra, ocular steroids, or any medication (Rx or over the counter (OTC)) that may interfere with contact lens wear (at the discretion of the investigator).
13. Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or corneal distortion.
14. Any Grade 3 or greater biomicroscopy findings (this includes, corneal edema, corneal staining, corneal vascularization, conjunctival injection, tarsal abnormalities, bulbar injection) on the FDA classification scale.

Minimum Eligible Age

18 Years

Maximum Eligible Age

59 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes